Table 2.
Baseline characteristics of HSP group and matched control group
| HSP Group (n = 333) | Matched Group (n = 999) | P | |
|---|---|---|---|
| Overall mortality rate | 19 (5.7) | 72 (7.2) | 0.35 |
| Pretransplant dialysis status | |||
| yes | 276 (86.8) | 783 (84.1) | 0.25 |
| no | 42 (13.2) | 148 (15.9) | |
| missing data | 15 | 68 | |
| Peak PRA (%) | |||
| median (range) | 0 (0 to 99) | 0 (0 to 99) | 0.80 |
| missing data | 38 | 122 | |
| HCV status (core antibody) | |||
| negative | 211 (98.6) | 628 (98.0) | 0.77 |
| positive | 3 (1.4) | 13 (2.0) | |
| missing data | 119 | 358 | |
| Donor age (years) | |||
| median (range) | 35 (2 to 66) | 37 (0 to 81) | 0.10 |
| Donor serum creatinine (mg/dl) | |||
| median (range) | 0.9 (0.2 to 9) | 0.9 (0.2 to 25) | 0.77 |
| missing data | 158 | 476 | |
| HLA mismatching | |||
| 0 | 30 (9) | 135 (13.7) | 0.12 |
| 1 | 17 (5.1) | 68 (6.9) | |
| 2 | 61 (18.4) | 163 (16.6) | |
| 3 | 92 (27.7) | 278 (28.3) | |
| 4 | 69 (20.8) | 155 (15.8) | |
| 5 | 41 (12.4) | 126 (12.8) | |
| 6 | 22 (6.6) | 59 (6) | |
| missing data | 1 | 15 | |
| Haplotype matching (LRD) | |||
| 0 | 26 (16.5) | 74 (15.9) | 0.76 |
| 0.5 | 1 (0.6) | 7 (1.5) | |
| 1 | 110 (69.6) | 307 (66.0) | |
| 1.5 | 7 (4.4) | 16 (3.4) | |
| 2 | 12 (7.6) | 55 (11.8) | |
| missing data | 9 | 36 | |
| HLA-DR mismatching | |||
| 0 | 86 (25.9) | 315 (32.0) | 0.06 |
| 1 | 192 (57.8) | 499 (50.7) | |
| 2 | 54 (16.3) | 170 (17.3) | |
| missing data | 1 | 15 | |
| Cold ischemia times (hours) | |||
| median (range) | 10 (0 to 59) | 8 (0 to 55) | 0.65 |
| missing data | 64 | 156 | |
| Warm ischemia times (min) | |||
| median (range) | 31 (0 to 97) | 31 (0 to 215) | 0.59 |
| missing data | 113 | 297 | |
| Immunosuppression at discharge | |||
| azathioprine | 143 (43.0) | 379 (38.0) | 0.20 |
| MMF | 136 (40.8) | 424 (42.4) | |
| neither | 47 (14.1) | 173 (17.3) | |
| cyclosporine | 216 (64.9) | 627 (62.8) | 0.79 |
| tacrolimus | 87 (26.1) | 276 (27.6) | |
| neither | 26 (7.8) | 85 (8.5) | |
| Follow-up time (years) | |||
| median (range) | 5.6 (0.01 to 20.0) | 5.6 (0.01 to 19.9) | 0.56 |
The data shown represent all patients in matched groups unless otherwise specified. HLA, human histocompatibility leukocyte antigen; HLA-DR, PRA, Panel Reactive Antibody; HCV, Hepatitis C Virus; MMF, mycophenolate mofetil; LRD, Living Related Donor.